Zobrazeno 1 - 10
of 317
pro vyhledávání: ''
Autor:
J Garg, Analia Alvarez, Elizabeth Zuta-Santillan, Paul Brunetta, Ana Malvar, Cary M. Looney, Brad H. Rovin, Thomas Schindler, Richard Furie, Matthew D Cascino, Imran Hassan, Gustavo Aroca, Hilda Fragoso-Loyo
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveRandomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell d
Publikováno v:
Annals of the Rheumatic Diseases. 80:1393-1399
BackgroundHepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence a
Autor:
Varun Dhir, Shefali Khanna Sharma, Amita Aggarwal, Siddharth Jain, Aastha Khullar, Bidyalaxmi Leishangthem, Supriya Maurya, Ranjan Gupta, Aman Sharma, Sanjay Jain, Shankar Naidu, Veena Dhawan
Publikováno v:
Annals of the Rheumatic Diseases. 80:1376-1384
ObjectivesThere are no head-to-head trials of different dose escalation strategies of methotrexate (MTX) in RA. We compared the efficacy, safety and tolerability of ‘usual’ (5 mg every 4 weeks) versus ‘fast’ (5 mg every 2 weeks) escalation of
Autor:
Kamran Naraghi, Désirée van der Heijde, Sarah Horton, Raluca B Dumitru, Paul Emery, Maya H Buch, Richard J. Wakefield, Elizabeth M A Hensor
Publikováno v:
Annals of the Rheumatic Diseases, 79(4), 464-471. BMJ PUBLISHING GROUP
Emery, P, Horton, S, Dumitru, R B, Naraghi, K, Heijde, D V D, Wakefield, R, Hensor, E M A & Buch, M 2020, ' A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial ', Annals of the rheumatic diseases, vol. 79, no. 4, pp. 464-471 . https://doi.org/10.1136/annrheumdis-2019-216539
Emery, P, Horton, S, Dumitru, R B, Naraghi, K, Heijde, D V D, Wakefield, R, Hensor, E M A & Buch, M 2020, ' A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial ', Annals of the rheumatic diseases, vol. 79, no. 4, pp. 464-471 . https://doi.org/10.1136/annrheumdis-2019-216539
ObjectivesWe sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN
Autor:
Xiufang Kong, Lili Ma, Ying Sun, Huiyong Chen, Zongfei Ji, Xuejuan Jin, Xiaojuan Dai, Lindi Jiang, Li Wang
Publikováno v:
Annals of the rheumatic diseases. 81(1)
ObjectiveTo compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK).MethodsFifty-three patients with active disease from an ongoing prospective TAK cohort in China were included in this stu
Autor:
Kunihiro Yamaoka, Heidi S. Camp, Peter Nash, Eduardo Mysler, Jeffrey R. Curtis, J. Suboticki, N. Khan, Y. Song, Kevin L. Winthrop
Publikováno v:
Annals of the Rheumatic Diseases
BackgroundUpadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA). JAK inhibitors have been associated with an increased risk of herpes zoster (HZ) in patients with RA.ObjectivesTo evaluate t
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveIdentify predictors of treatment failure in patients with giant cell arteritis (GCA) receiving tocilizumab in combination with glucocorticoids and in patients with GCA receiving only glucocorticoids.MethodsPosthoc analysis of the Giant-Cell
Autor:
Camille P. Figueiredo, Georg Schett, Stephanie Finzel, Juergen Rech, Adrian P. Regensburger, Sebastian Krauß, Roland Kocijan
Publikováno v:
Annals of the Rheumatic Diseases. 78:1186-1191
ObjectiveTo compare the effects of interleukin-6 (IL-6) receptor and tumour necrosis factor inhibition on inducing repair of existing bone erosions in patients with very early rheumatoid arthritis (RA).MethodsProspective non-randomised observational
Autor:
Jürgen Steffgen, Steven J. Padula, Ulf Müller-Ladner, Christian Schwabe, Stefan Daniluk, Meera Ramanujam, Patrick Baum, Eva Dokoupilova, Herbert Kellner, Bernd Rosenstock, Rieke Alten, Brygida Kwiatkowska, Sudha Visvanathan, Rafał Ptaszyński, Anastasia G. Eleftheraki, Jay S. Fine, David Joseph, Richard Vinisko, Alena Petříková
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR).MethodsIn total, 67 patien
Autor:
Dominique Baeten, Inka A. Fluri, Marleen G H van de Sande, Marc R. Kok, Arno W R van Kuijk, Henriëtte M. de Jong, Leonieke J J van Mens, Michael T. Nurmohamed
Publikováno v:
Annals of the rheumatic diseases, 78(5), 610-616. BMJ Publishing Group
van Mens, L J J, de Jong, H M, Fluri, I, Nurmohamed, M T, van de Sande, M G H, Kok, M, van Kuijk, A W R & Baeten, D 2019, ' Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: A double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate ', Annals of the Rheumatic Diseases, vol. 78, no. 5, pp. 610-616 . https://doi.org/10.1136/annrheumdis-2018-214746
Annals of the Rheumatic Diseases, 78(5), 610-616. BMJ Publishing Group
van Mens, L J J, de Jong, H M, Fluri, I, Nurmohamed, M T, van de Sande, M G H, Kok, M, van Kuijk, A W R & Baeten, D 2019, ' Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: A double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate ', Annals of the Rheumatic Diseases, vol. 78, no. 5, pp. 610-616 . https://doi.org/10.1136/annrheumdis-2018-214746
Annals of the Rheumatic Diseases, 78(5), 610-616. BMJ Publishing Group
ObjectivesEarly initiation of effective treatment favours remission in rheumatoid arthritis, but it remains unknown if the same concept applies to psoriatic arthritis (PsA). Therefore, this study investigated whether the combination of golimumab plus